Keymed Biosciences Licenses CM355 to Prolium for Global Development

An update from Keymed Biosciences, Inc. ( (HK:2162) ) is now available.

Keymed Biosciences Inc. has entered into a licensing agreement with Prolium for the global development and commercialization of CM355, excluding Asia in oncology indications. CM355, a CD20×CD3 bispecific antibody, is in clinical trials and has shown promising results in treating non-Hodgkin lymphoma. The agreement, which includes significant financial terms and milestone payments, positions Keymed strategically in the biopharmaceutical industry, potentially enhancing its market presence and financial standing.

More about Keymed Biosciences, Inc.

Keymed Biosciences Inc. is a biopharmaceutical company focused on developing innovative therapeutic products, particularly in the area of oncology and autoimmune diseases. The company is known for creating bispecific antibodies, with a significant market focus on both oncology and non-oncology fields.

YTD Price Performance: -5.18%

Average Trading Volume: 1,587,992

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$7.67B

For detailed information about 2162 stock, go to TipRanks’ Stock Analysis page.